Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 20 | ECE2009 | Next issue

11th European Congress of Endocrinology

Oral Communications

Acromegaly/IGF1/Type 2 Diabetes

ea0020oc4.1 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial

Giustina Andrea , Bonadonna Stefania , Bugari Giovanna , Colao Annamaria , Cozzi Renato , Cannavo Salvatore , De Marinis Laura , degli Uberti Ettore , Bogazzi Fausto , Mazziotti Gherardo , Minuto Francesco , Montini Marcella , Ghigo Ezio

Objective: In acromegaly, 25–50% of patients remain uncontrolled with conventional somatostatin analogue (SA) therapy. Evidence suggests that response may be improved by increasing the dose or frequency of administration of SAs. This study evaluated the efficacy and safety of octreotide LAR administered at a high dose or high frequency in patients with acromegaly.Methods: This was a 24-week prospective, multicenter, randomized, open-label trial in p...

ea0020oc4.2 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Both insulin resistance and insulin secretion are involved in the pre-diabetes of acromegaly

Niculescu Dan , Purice Mariana , Lichiardopol Radu , Coculescu Mihail

In acromegalic patients growth hormone (GH) excess induces insulin resistance but whether this is sufficient, in the face of normal insulin secretion, for pre-diabetes (impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)) to occur is a matter of debate.Aim: To assess the relative role of insulin resistance and insulin secretion in the pre-diabetes of acromegaly.Methods: One hundred and twenty-four patients with acro...

ea0020oc4.3 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin (SST), growth hormone (GH)-releasing hormone (GHRH) and ghrelin in a non-human primate (Papio anubis)

Chacon Jose Cordoba , Castano Justo P , Kineman Rhonda D , Luque Raul M

Secretion of GH by pituitary somatotropes is primarily stimulated by GHRH and ghrelin and inhibited by SST through the activation of specific receptors (GHRH-R, GHS-R and Sstr1-5, respectively). However, we have previously shown that SST, at low doses, can also stimulate GH release, directly and specifically, in primary pituitary cell cultures from baboons (Papio anubis) and pigs. To determine whether these primary regulators of GH release can also regulate directly the...

ea0020oc4.4 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Development of a novel anti-IGF1 receptor immunoliposomal cancer therapy with enhanced therapeutic efficiency

Hantel Constanze , Lewrick Felicitas , Schneider Sebastian , Zwermann Oliver , Reincke Martin , Peschka-Suss Regine , Beuschlein Felix

Overexpression and aberrant activation of the insulin-like growth factor system plays a key role in tumor cell proliferation and tumorigenesis in many human tumors. Different therapies targeting IGF1-receptor (IGF1-R) have been developed and currently, some of these agents are evaluated in preclinical and early clinical trials with promising results. Moreover, recent studies have demonstrated that combined treatments with doxorubicin, enhance the efficiency of anti-IGF1-R ther...

ea0020oc4.5 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Regulation of obestatin levels during unacylated ghrelin infusions in normal and type 2 diabetic patients

St-Pierre David H , Settanni Fabio , Olivetti Ilaria , Gramaglia Elena , Benso Andrea , Riganti Fabrizio , Ghigo Ezio , Broglio Fabio

Background: Obestatin, a ghrelin gene product was recently isolated but important questions remain regarding its regulation and its physiological effects. The aim of the present study was to evaluate the effect of unacylated ghrelin (UAG) on obestatin levels in normal subjects and patients with type 2 diabetes (T2D).Methods: Five normal subjects and 5 T2D patients were included in this study. Unacylated ghrelin (3 μg/kg per hour) or saline were cont...

ea0020oc4.6 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Cardiovascular effects of chronic Sildenafil treatment in men with type 2 diabetes

Isidori Andrea , Giannetta Elisa , Carbone Iacopo , Vizza Dario , Orano Susanna , Vingolo Enzo , Bonifacio Vincenzo , Lenzi Andrea

In type 2 diabetes (T2DM), cardiomiopathy is characterized by an impairment of diastolic performance resulting in ventricular hypertrophy and dilatation. Heart remodelling leads to an increase in its angle of torsion, measurable by innovative cine-magnetic resonance imaging (MRI). To evaluate the impact of phosphodiesterase 5 inhibitors (PDE5i) on cardiovascular performance in T2DM, we designed a randomized, placebo-controlled, double blind (subject/outcome assessor) study on ...